Corvus Pharmaceuticals : SID Q1 Conf Call Presentation FINAL

Published: 2025-05-09 05:15:28 ET CRVS

Published on 05/09/2025 at 05:15

Conference Call & Webcast

May 8, 2025

First Quarter 2025 Financial Results

Soquelitinib Atopic Dermatitis Phase 1 Data

Business Update

Q&A

3

Today's Agenda

Albert S. Chiou, MD

Clinical Associate Professor, Dermatology and Director of Clinical Research in

the Department of Dermatology Stanford University Medical Center

Albert S. Chiou1, James T. Rosenbaum2, Lih-Yun Hsu2, Dan Li2, Gabriel Luciano2, Suresh Mahabhashyam2, Richard Miller2

1 Stanford Medical Center, Palo Alto, CA, United States; 2 Corvus Pharmaceuticals Inc, So. San Francisco, CA, United States

Randomized 3:1

Placebo N = 4

Soquelitinib 100 mg BID N = 12

Cohort 1

N =16

Randomized 3:1

Placebo

N = 4

Soquelitinib 200 mg QD N = 12

Cohort 2

N = 16

Randomized 3:1

Placebo N = 4

Soquelitinib 200 mg BID N = 12

Cohort 3

N = 16

Randomized

3:1

Placebo

N = 4

Soquelitinib 400 mg QD N = 12

Cohort 4

N = 16

Treat for 28 days + 30-day follow-up

At least 1 prior topical or systemic therapy

Participants with moderate to severe AD

N = 64

Design: Randomized, placebo-controlled, blinded study in moderate to severe AD

Endpoints: Safety, EASI, IGA, biomarkers

Key Inclusion Criteria

Age ≥18 years of age

Hanifin C Rajka criteria

Moderate to severe disease; EASI ≥16; BSA ≥10; and vIGA ≥3

Inadequate response or intolerance to

at least one topical or systemic therapy

Key Exclusion Criteria

Other active skin disease or infection

TCS within 1 week, oral CS within 2 weeks or parenteral CS within 4 weeks

Oral or injectable immunosuppressive

meds within 4 weeks

Key Details

= enrollment completed 6

Soquelitinib Phase 1 AD Study Design

Disclaimer

Corvus Pharmaceuticals Inc. published this content on May 08, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 09, 2025 at 04:59 UTC.